Percheron Therapeutics (ASX:PER) has ended its American Depository Receipt (ADR) facility with financial services provider BNY Mellon, according to a Tuesday filing with the Australian bourse.
The ADR, trading with the ticker 'ATHJY' will no longer be quoted via over-the-counter (OTC) markets, the filing said.
The biotechnology company has now uplisted its foreign shares (F shares), trading with the ticker 'ATHJF', to the Over-the-Counter Bulletin Board (OTCQB) tier of the OTC markets.
The company has applied to the US Financial Industry Regulatory Authority for sponsorship of its F shares and a ticker change from 'ATHJF' to 'PERCF.'
These moves are expected to improve access to the company's securities to US investors and reduce costs for the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。